Coloplast A/S (CLPBY)
12.56
+0.20
(+1.62%)
USD |
OTCM |
May 17, 16:00
Coloplast Net Income (Quarterly): 182.36M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 182.36M |
| December 31, 2023 | 174.92M |
| September 30, 2023 | 179.48M |
| June 30, 2023 | 185.91M |
| March 31, 2023 | 166.57M |
| December 31, 2022 | 154.93M |
| September 30, 2022 | 166.52M |
| June 30, 2022 | 184.53M |
| March 31, 2022 | 147.83M |
| December 31, 2021 | 185.65M |
| September 30, 2021 | 206.90M |
| June 30, 2021 | 203.23M |
| March 31, 2021 | 183.18M |
| December 31, 2020 | 181.97M |
| September 30, 2020 | 163.53M |
| June 30, 2020 | 147.24M |
| March 31, 2020 | 157.52M |
| December 31, 2019 | 161.88M |
| September 30, 2019 | 118.13M |
| June 30, 2019 | 160.68M |
| March 31, 2019 | 155.39M |
| December 31, 2018 | 151.50M |
| September 30, 2018 | 162.02M |
| June 30, 2018 | 151.90M |
| March 31, 2018 | 151.45M |
| Date | Value |
|---|---|
| December 31, 2017 | 148.74M |
| September 30, 2017 | 159.62M |
| June 30, 2017 | 134.55M |
| March 31, 2017 | 133.37M |
| December 31, 2016 | 137.17M |
| September 30, 2016 | 63.58M |
| June 30, 2016 | 148.47M |
| March 31, 2016 | 135.43M |
| December 31, 2015 | 120.98M |
| September 30, 2015 | -211.77M |
| June 30, 2015 | 104.98M |
| March 31, 2015 | 123.44M |
| December 31, 2014 | 133.74M |
| September 30, 2014 | 149.55M |
| June 30, 2014 | 144.81M |
| March 31, 2014 | -3.488M |
| December 31, 2013 | 142.33M |
| September 30, 2013 | 133.11M |
| June 30, 2013 | 124.37M |
| March 31, 2013 | 112.38M |
| December 31, 2012 | 107.29M |
| September 30, 2012 | 102.07M |
| June 30, 2012 | 101.53M |
| March 31, 2012 | 90.63M |
| December 31, 2011 | 87.64M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
118.13M
Minimum
Sep 2019
206.90M
Maximum
Sep 2021
170.65M
Average
170.74M
Median
Net Income (Quarterly) Benchmarks
| Genmab A/S | 193.00M |
| Ascendis Pharma A/S | -142.33M |
| Galecto Inc | -5.477M |
| Evaxion Biotech AS | -4.523M |
| IO Biotech Inc | -19.46M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 959.30M |
| Total Expenses (Quarterly) | 698.43M |
| EPS Diluted (Quarterly) | 0.0811 |
| Enterprise Value | 31.53B |
| Gross Profit Margin (Quarterly) | 67.98% |
| Profit Margin (Quarterly) | 19.01% |
| Earnings Yield | 2.60% |
| Operating Earnings Yield | 3.69% |
| Normalized Earnings Yield | 2.588 |